Breaking Finance News

Zacks Investment Research upgraded QLT Inc. (USA) (NASDAQ:QLTI) to Hold in a report released today.

Zacks Investment Research has upgraded QLT Inc. (USA)(NASDAQ:QLTI) to Hold in a report released on Monday September 19 2016.

Yesterday QLT Inc. (USA) (NASDAQ:QLTI) traded 0.68% lower at $1.59. The company’s 50-day moving average is $1.43 and its two hundred day average is $1.60. With the last close down 1.98% relative to the two hundred day moving average, compared with the S&P 500 which has decreased -0.01% over the same time. 76,233 shares of QLT Inc. (USA) traded hands, down from ann avg. volume of 205,934.

Performance Graphic:


QLT Inc. (USA) has a one-year low of $1.22 and a 52 week high of $3.58 and has a total market value of $0.0.

Brief Synopsis About QLT Inc. (USA) (NASDAQ:QLTI)

QLT Inc. is a biotechnology company. The Company is focused on the development and commercialization of ocular products. The Company’s operations consist of clinical development programs focused on its synthetic retinoid, QLT091001, for the treatment of certain age-related and inherited retinal diseases (IRD) caused by retinal pigment epithelium protein 65 (RPE65) and lecithin: retinol acyltransferase (LRAT) gene mutations. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal. The Company is developing QLT091001 for the treatment of IRD caused by RPE65 and LRAT gene mutations, which indication includes Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP). It has completed a Phase Ib clinical proof of concept study and a follow-up retreatment study in LCA and RP patients with autosomal recessive mutations in RPE65 or LRAT, and and a Phase 1b study in RP patients with autosomal dominant mutations in RPE65.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *